Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | SARS-CoV-2 | Case report

Case report: change of dominant strain during dual SARS-CoV-2 infection

Authors: Andrei E. Samoilov, Valeriia V. Kaptelova, Anna Y. Bukharina, Olga Y. Shipulina, Elena V. Korneenko, Stepan S. Saenko, Alexander V. Lukyanov, Antonina A. Grishaeva, Antonina A. Ploskireva, Anna S. Speranskaya, Vasiliy G. Akimkin

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

The dual infection with SARS-CoV-2 is poorly described and is currently under discussion. We present a study of two strains of SARS-CoV-2 detected in the same patient during the same disease presentation.

Case presentation

A patient in their 90 s was hospitalised with fever. Oropharyngeal swab obtained on the next day (sample 1) tested positive for SARS-CoV-2. Five days later, the patient was transferred to the ICU (intensive care unit) of the hospital specialising in the treatment of COVID-19 patients, where the patient's condition progressively worsened and continuous oxygen insufflation was required. Repeated oropharyngeal swab (sample 2), which was taken eight days after the first one, also tested positive for SARS-CoV-2. After 5 days of ICU treatment, the patient died. The cause of death was a coronavirus infection, which progressed unfavourably due to premorbid status. We have performed sequencing of full SARS-CoV-2 genomes from oropharyngeal swabs obtained eight days apart. Genomic analysis revealed the presence of two genetically distant SARS-CoV-2 strains in both swabs. Detected strains belong to different phylogenetic clades (GH and GR) and differ in seven nucleotide positions. The relative abundance of strains was 70% (GH) and 30% (GR) in the first swab, and 3% (GH) and 97% (GR) in the second swab.

Conclusions

Our findings suggest that the patient was infected by two genetically distinct SARS-CoV-2 strains at the same time. One of the possible explanations is that the second infection was hospital-acquired. Change of the dominant strain ratio during disease manifestation could be explained by the advantage or higher virulence of the GR clade strain.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, et al. Dual HIV-1 infection associated with rapid disease progression. Lancet. 2004;363:619–22.CrossRef Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, et al. Dual HIV-1 infection associated with rapid disease progression. Lancet. 2004;363:619–22.CrossRef
2.
go back to reference van der Kuyl AC, Cornelissen M. Identifying HIV-1 dual infections. Retrovirology. 2007;4:67.CrossRef van der Kuyl AC, Cornelissen M. Identifying HIV-1 dual infections. Retrovirology. 2007;4:67.CrossRef
3.
go back to reference Ekouevi DK, Eholie SP. Update on HIV-1 and HIV-2 dual infection. In: Encyclopedia of AIDS. Springer New York: New York, NY, 2013, pp 1–10. Ekouevi DK, Eholie SP. Update on HIV-1 and HIV-2 dual infection. In: Encyclopedia of AIDS. Springer New York: New York, NY, 2013, pp 1–10.
4.
go back to reference Myers CA, Kasper MR, Yasuda CY, Savuth C, Spiro DJ, Halpin R, et al. Dual infection of novel influenza viruses A/H1N1 and A/H3N2 in a cluster of Cambodian patients. Am J Trop Med Hyg. 2011;85:961–3.CrossRef Myers CA, Kasper MR, Yasuda CY, Savuth C, Spiro DJ, Halpin R, et al. Dual infection of novel influenza viruses A/H1N1 and A/H3N2 in a cluster of Cambodian patients. Am J Trop Med Hyg. 2011;85:961–3.CrossRef
5.
go back to reference Weinberg A, Bloch KC, Li S, Tang Y, Palmer M, Tyler KL. Dual infections of the central nervous system with Epstein–Barr virus. J Infect Dis. 2005;191:234–7.CrossRef Weinberg A, Bloch KC, Li S, Tang Y, Palmer M, Tyler KL. Dual infections of the central nervous system with Epstein–Barr virus. J Infect Dis. 2005;191:234–7.CrossRef
9.
go back to reference Wang W, Le Grange JM, Wang X, Du S, Li C, et al. Coinfection of SARS-CoV-2 and other respiratory pathogens. Infect Drug Resist. 2020;13:3045–53.CrossRef Wang W, Le Grange JM, Wang X, Du S, Li C, et al. Coinfection of SARS-CoV-2 and other respiratory pathogens. Infect Drug Resist. 2020;13:3045–53.CrossRef
10.
go back to reference Miatech JL, Tarte NN, Katragadda S, Polman J, Robichaux SB. A case series of coinfection with SARS-CoV-2 and influenza virus in Louisiana. Respir Med Case Rep. 2020;31: 101214.PubMedPubMedCentral Miatech JL, Tarte NN, Katragadda S, Polman J, Robichaux SB. A case series of coinfection with SARS-CoV-2 and influenza virus in Louisiana. Respir Med Case Rep. 2020;31: 101214.PubMedPubMedCentral
11.
go back to reference Castillo EM, Coyne CJ, Brennan JJ, Tomaszewski CA. Rates of coinfection with other respiratory pathogens in patients positive for coronavirus disease 2019 (COVID-19). J Am Coll Emerg Physicians Open. 2020;1:592–6.CrossRef Castillo EM, Coyne CJ, Brennan JJ, Tomaszewski CA. Rates of coinfection with other respiratory pathogens in patients positive for coronavirus disease 2019 (COVID-19). J Am Coll Emerg Physicians Open. 2020;1:592–6.CrossRef
13.
go back to reference Sharov KS. SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March–May 2020: secondary bacterial pneumonia and viral co-infections. J Glob Health. 2020;10:20504.CrossRef Sharov KS. SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March–May 2020: secondary bacterial pneumonia and viral co-infections. J Glob Health. 2020;10:20504.CrossRef
15.
go back to reference Johnston R. The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals. Curr Opin HIV AIDS. 2021;16:54–62.CrossRef Johnston R. The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals. Curr Opin HIV AIDS. 2021;16:54–62.CrossRef
16.
go back to reference Roncati L, Lusenti B, Nasillo V, Manenti A. Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease. Ann Hematol. 2020;99:1945–6.CrossRef Roncati L, Lusenti B, Nasillo V, Manenti A. Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease. Ann Hematol. 2020;99:1945–6.CrossRef
17.
go back to reference Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol. 2020;104:7777–85.CrossRef Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol. 2020;104:7777–85.CrossRef
18.
go back to reference Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26:1395–9.CrossRef Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26:1395–9.CrossRef
20.
go back to reference Hashim H, Mohammed M, Mousa M, Abdulameer H, Alhassnawi A, Hassan S, et al. Infection with different strains of SARS-COV-2 in patients with COVID-19. Arch Biol Sci. 2020;72(575–585):51–51. Hashim H, Mohammed M, Mousa M, Abdulameer H, Alhassnawi A, Hassan S, et al. Infection with different strains of SARS-COV-2 in patients with COVID-19. Arch Biol Sci. 2020;72(575–585):51–51.
22.
go back to reference Davidson CJ, Zeringer E, Champion KJ, Gauthier M-P, Wang F, Boonyaratanakornkit J, et al. Improving the limit of detection for Sanger sequencing: a comparison of methodologies for KRAS variant detection. Biotechniques. 2012;53:182–8.CrossRef Davidson CJ, Zeringer E, Champion KJ, Gauthier M-P, Wang F, Boonyaratanakornkit J, et al. Improving the limit of detection for Sanger sequencing: a comparison of methodologies for KRAS variant detection. Biotechniques. 2012;53:182–8.CrossRef
23.
go back to reference Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020;383:2291–3.CrossRef Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020;383:2291–3.CrossRef
25.
go back to reference Nyayanit D, Yadav P, Kharde R, Shete-Aich A. Quasispecies analysis of the SARS-CoV-2 from representative clinical samples: a preliminary analysis. Indian J Med Res. 2020;152:105.PubMedPubMedCentral Nyayanit D, Yadav P, Kharde R, Shete-Aich A. Quasispecies analysis of the SARS-CoV-2 from representative clinical samples: a preliminary analysis. Indian J Med Res. 2020;152:105.PubMedPubMedCentral
26.
go back to reference Jary A, Leducq V, Malet I, Marot S, Klement-Frutos E, Teyssou E, et al. Evolution of viral quasispecies during SARS-CoV-2 infection. Clin Microbiol Infect. 2020;26(1560):e1-1560.e4. Jary A, Leducq V, Malet I, Marot S, Klement-Frutos E, Teyssou E, et al. Evolution of viral quasispecies during SARS-CoV-2 infection. Clin Microbiol Infect. 2020;26(1560):e1-1560.e4.
28.
go back to reference Zhang Z, Wang F-S. SARS-associated coronavirus quasispecies in individual patients. N Engl J Med. 2004;350:1366–7.CrossRef Zhang Z, Wang F-S. SARS-associated coronavirus quasispecies in individual patients. N Engl J Med. 2004;350:1366–7.CrossRef
29.
go back to reference Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020;173:262–7.CrossRef Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020;173:262–7.CrossRef
30.
go back to reference Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92:441–7.CrossRef Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92:441–7.CrossRef
32.
go back to reference Gupta AM, Chakrabarti J, Mandal S. Non-synonymous mutations of SARS-CoV-2 leads epitope loss and segregates its variants. Microbes Infect. 2020;22:598–607.CrossRef Gupta AM, Chakrabarti J, Mandal S. Non-synonymous mutations of SARS-CoV-2 leads epitope loss and segregates its variants. Microbes Infect. 2020;22:598–607.CrossRef
35.
go back to reference Chan AP, Choi Y, Schork NJ. Conserved genomic terminals of SARS-CoV-2 as coevolving functional elements and potential therapeutic targets. mSphere. 2020;5: e00754-20.CrossRef Chan AP, Choi Y, Schork NJ. Conserved genomic terminals of SARS-CoV-2 as coevolving functional elements and potential therapeutic targets. mSphere. 2020;5: e00754-20.CrossRef
38.
go back to reference Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11:6013.CrossRef Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11:6013.CrossRef
39.
go back to reference Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812-827.e19.CrossRef Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812-827.e19.CrossRef
40.
go back to reference Nie J, Zhang L, Hao H, Liu S, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182:1284-1294.e9.CrossRef Nie J, Zhang L, Hao H, Liu S, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182:1284-1294.e9.CrossRef
42.
go back to reference Eaaswarkhanth M, Al Madhoun A, Al-Mulla F. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality? Int J Infect Dis. 2020;96:459–60.CrossRef Eaaswarkhanth M, Al Madhoun A, Al-Mulla F. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality? Int J Infect Dis. 2020;96:459–60.CrossRef
44.
go back to reference Eskier D, Karakülah G, Suner A, Oktay Y. RdRp mutations are associated with SARS-CoV-2 genome evolution. PeerJ. 2020;8: e9587.CrossRef Eskier D, Karakülah G, Suner A, Oktay Y. RdRp mutations are associated with SARS-CoV-2 genome evolution. PeerJ. 2020;8: e9587.CrossRef
Metadata
Title
Case report: change of dominant strain during dual SARS-CoV-2 infection
Authors
Andrei E. Samoilov
Valeriia V. Kaptelova
Anna Y. Bukharina
Olga Y. Shipulina
Elena V. Korneenko
Stepan S. Saenko
Alexander V. Lukyanov
Antonina A. Grishaeva
Antonina A. Ploskireva
Anna S. Speranskaya
Vasiliy G. Akimkin
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06664-w

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.